Team & Advisory Board

Founders

Peter Leonardi Ph.D., M.B.A.

Founder and CEO of OmniCyte. Dr. Leonardi’s previous positions include: CFO of Protein Sciences a private biotech company (sold to Sanofi $750M), Director at Five Prime Advisors (a boutique Biotech Investment Bank) where he focused on private placements and company valuations, VP of Channel Development at ProCure Treatment Centers (a VC backed healthcare company), IBM and the NY Presbyterian Hospital (University hospital of Cornell and Columbia). Dr. Leonardi has served on the Columbia University Institutional Review Board (IRB), the Genomics Formulary Committee of New York Presbyterian Hospital and the Cancer Biotherapeutics Development study section for the National Cancer Institute.

Angel Pellicer, M.D., Ph.D. 

Founder and Investigator.  Dr. Pellicer is a Professor of Pathology, Director, Molecular Oncology and Immunology Training Program, and Associate Director of the NYU Cancer Institute.  Angel was a post-doc in the laboratory of  the Nobel Laureate Dr. Richard Axel at Columbia University, where he was first author on the majority of the work that generated the greatest royalty stream of any biotechnology in the 20th century. Patents for his work in eukaryotic transfection earned more than $900 million for Columbia University.

Team

Edward J. Quinlan, Ph.D. 

Immunologist, Yale School of Medicine, lab of Leiping Chen (Dr. Chen initiated the first-in-man clinical trial of anti-PD-1 monoclonal antibody for treating human cancer in 2006).

Alexander Serganov, Ph.D. 

Assistant Professor NYU Dept. of Pharmacology & Biochemistry. 

Rick Chubet

Protein chemist (previously Protein Sciences Corp).

Board of Advisors

Lieping Chen, MD, Ph.D. 

United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology); Co-Director, Cancer Immunology Program at Yale Cancer Center. Dr. Chen established the foundation for the anti-PD-1/PD-L1 therapy for human cancer.  Dr. Chen also pioneered the first proof-of-concept study showing that manipulation of the B7-CD28/CTLA-4 could be used for cancer immunotherapy. 

Dmitriy Zamarin, M.D., Ph.D.  

Assistant Attending Physician MSKCC, Gynecologic Medical Oncology and immunotherapeutics Services at Memorial Sloan Kettering in the lab of Jedd Wolchok.

Gil G Mor, MD, Ph.D., MSc 

Professor of Obstetrics, Gynecology, and Reproductive Sciences Yale School of Medicine; Division Director, Reproductive Sciences; Director Reproductive Immunology Unit and Discovery to Cure Program.

Alan Frey, Ph.D. 

Associate Professor of Cell Biology NYU Medical Center. Leads research projects in “engineering the immune response to "self" for effective cancer immunotherapy” and studying the “suppression of T cell responses in the tumor microenvironment.”

Alexander Serganov, Ph.D. 

Assistant Professor, Department of Biochemistry and Molecular Pharmacology NYU Medical Center.  Dr Serganov has served as PI and Co-investigator on three grants conducted in collaboration between OmniCyte and NYU Medical Center. 

William Carroll, M.D. 

Director NYU Cancer Institute, Chief Pediatric Hematology/Oncology and Chair of the Children’s Oncology ALL Group,  directs the largest children’s cancer clinical trials network worldwide.

Manon Cox Ph.D., M.B.A.

Head of Vaccine Development, Dr Cox leads the SARS-CoV-2 vaccine development program. Previously, Dr Cox led the development of Flublok®, the only FDA approved recombinant influenza vaccine, while serving as CEO of Protein Sciences Corp. (sold to Sanofi for $750M).  Dr Cox also developed a recombinant vaccine against the original SAR-CoV.

© 2020 by OmniCyte LLC